Bank Julius Baer & Co. Ltd, Zurich Supernus Pharmaceuticals, Inc. Transaction History
Bank Julius Baer & Co. Ltd, Zurich
- $25.6 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding SUPN
# of Institutions
281Shares Held
60.6MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$386 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$228 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$189 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$107 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$97.9 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.99B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...